SCHEMBL15328003

SCHEMBL15328003

NC(=O)N1CCN(c2ccc(Cl)cc2)C1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.46
DRD3 P35462 1/20 0.46
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KMT2A Q03164 2/20 0.40
P2RX7 Q99572 1/20 0.40
MEN1 O00255 1/20 0.40
BRD4 O60885 1/20 0.39
BRD2 P25440 1/20 0.39
CHIA Q9BZP6 1/20 0.39
CMA1 P23946 2/20 0.39
CTSG P08311 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
AKR1C3 P42330 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15328043 0.83 DRD2 (0.46) DRD2DRD3NPC1RAB9AKMT2A
SCHEMBL13926363 0.83 RAB9A (0.50) DRD2DRD3NPC1RAB9AKMT2A
SCHEMBL5585348 0.83 MEN1 (0.62) DRD2DRD3NPC1RAB9AKMT2A
SCHEMBL15328097 0.83 HTR2A (0.54) DRD2DRD3P2RX7ALDH1A1LMNA
SCHEMBL15327905 0.83 DRD2 (0.46) DRD2DRD3CMA1CTSGHDAC1
SCHEMBL15328068 0.80 HDAC1 (0.49) KMT2AMEN1HDAC1HDAC8HDAC6
SCHEMBL15328109 0.80 PARP1 (0.46) NPC1RAB9AKMT2AMEN1HDAC1
SCHEMBL15328020 0.80 HDAC1 (0.48) NPC1RAB9AKMT2AMEN1HDAC1
SCHEMBL430722 0.78 DRD2 (0.43) DRD2DRD3NPC1RAB9AKMT2A
SCHEMBL9673108 0.78 F10 (0.36) NPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP claimed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US claimed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US claimed
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US disclosed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ING2, CDK2, MAP3K20 DRD2 2444/4885DRD3 3146/4885NPC1 3108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.